Abstract Human genetic peroxisomal biogenesis disorders (PBDs), such as Zellweger syndrome, comprise 13 different complementation groups (CGs). Eleven peroxin genes, termed PEXs, responsible for PBDs have been identified, whereas pathogenic genes for PBDs of 2 CGs, CG-A (the same CG as CG8 in the United States and Europe) and CG6, remained unidentified. We herein provide several lines of novel evidence indicating that PEX6, the pathogenic gene for CG4, is impaired in PBD of CG6. Expression of PEX6 restored peroxisome assembly in fibroblasts from a CG6 PBD patient. This patient was a compound heterozygote for PEX6 gene alleles. Accordingly, by merging CG6 with CG4, human PBDs are now classified into 12 CGs.
Introduction
Human fatal genetic peroxisomal biogenesis disorders (PBDs; MIM 601539) include Zellweger syndrome (ZS; MIM 214100), neonatal adrenoleukodystrophy (NALD; MIM 202370), infantile Refsum disease (IRD; MIM 266510), and rhizomelic chondrodysplasia punctata (RCDP; MIM 215100) (Lazarow and Moser 1995) . Genetic heterogeneity, comprising 16 different complementation groups (CGs), has been identified in mammals, including 13CGs of PBDs and 3 distinct CGs of mutant Chinese hamster ovary (CHO) cell lines, as determined by cellfusion and/or peroxin gene (PEX) transfection, using fibroblasts from patients with PBDs and peroxisome-deficient CHO cell mutants (Ghaedi et al. 1999; Fujiki 2000 ) (see Table 1 ). The primary cause responsible for the peroxisome deficiency in the 13 CGs of PBDs is a failure in peroxisome biogenesis (Fujiki 2000; Gould and Valle 2000) . Eleven PEX genes involved in peroxisome biogenesis -PEX1, PEX2, PEX3, PEX5, PEX6, PEX7, PEX10, PEX12, PEX13, PEX16 , and PEX19 -have been identified as the genetic-related cause responsible for PBD groups E in Japan (CG1 in the United States and Europe), F (CG10), G (CG12), CG2, C (CG4), R (CG11), B (CG7), CG3, H (CG13), D (CG9), and J (CG14), respectively (Fujiki 2000; Gould and Valle 2000; Ghaedi et al. 2000; Shimozawa et al. 2000; Muntau et al. 2000; South et al. 2000) . Thus, pathogenic genes responsible for two CGs, CG-A (CG8) and CG6, remain to be isolated (Fujiki 2000; Ghaedi et al. 2000) .
The fibroblast cell line from a CG6 patient (PBD6-01) with NALD (patient 6 in the report of Kelly et al. (1986) ) was difficult to study because of poor growth. PBD6-01 cells were previously shown to complement CG1 cells in cellfusion analysis . In regard to complementation with CG4 cell lines, it was concluded that CG6 was distinct from CG4, after repeated analyses with borderline results . PBD6-01 is the only patient whose CG assignment had remained in doubt until now. In an earlier publication , three patients were assigned to CG6. Subsequently, two of these patients were found to have mutations in PEX6 (Yahraus et al. 1996) , and they were therefore reassigned to CG4. Earlier efforts to demonstrate a mutation in patient PBD6-01 had been unsuccessful. This, combined with the equivocal results of biochemical studies referred to earlier, had made it impossible to exclude the existence of CG6, prior to the new mutation analysis presented here. In this report, we provide several lines of novel evidence at the molecular level, indicating that CG6 is the same CG as CG4.
Materials and methods

Cell lines
Skin fibroblast cell lines from patients, including fibroblasts from a CG6 patient (PBD6-01) with NALD (Kelly et al. 1986 ), were cultured in Dulbecco's modified Eagle's medium-high glucose (DMEM) supplemented with 10% fetal bovine serum, as described (Shimozawa et al. 1992) . CHO cell mutants, including pex6 ZP92 (Shimozawa et al. 1992; Tsukamoto et al. 1995) and pex1 ZP107 ), were cultured as described.
Cell fusion and DNA transfection Parent fibroblasts and cells to be fused were cocultured for 1 day and then fused using polyethylene glycol, as described (Shimozawa et al. 1992; Tsukamoto et al. 1990 ). Cells were stained using specific antibodies 3 days after cell fusion. DNA transfection was performed by electroporation, using a Gene Pulser II electroporator (Bio-Rad, Hercules, CA, USA) with the setting of 320 V/500 µF and by lipofection, using Lipofectamine (Life Technologies, Tokyo, Japan) as described ).
Morphological analysis
Peroxisomes in human fibroblasts and CHO cells were visualized by indirect immunofluorescence microscopy, as described (Shimozawa et al. 1992) . Rabbit antibody to human catalase (Sigma, St. Louis, MO, USA) was raised by conventional subcutaneous injection. Antigen-antibody complexes were detected by fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit immunoglobulin G (IgG) antibody (Cappel, Durham, NC, USA), under an Axioskop FL microscope (Carl Zeiss, Oberkochen, Germany).
Isolation of PEX6
Human PEX6 cDNA was cloned by colony hybridization of a human liver cDNA library ), using as a probe a partial sequence of PEX6 (Fukuda et al. 1996) amplified by polymerase chain reaction (PCR) with a set of primers comprising nucleotide residues at 2375-2393 and 2913-2943. Subsequent sequencing of a cDNA clone was done by the dideoxy-chain termination method, using a Dye-terminator DNA sequence kit (Applied Biosystems, Foster City, CA, USA), as described ).
Mutation analysis Poly(A)
ϩ RNA was obtained from cultured patient's fibroblasts, using a QuickPrep Micro mRNA Purification kit (Amersham Pharmacia Biotech, Tokyo, Japan). Reverse transcription (RT)-PCR was done as described (Honsho et al. 1998) , using poly(A) ϩ RNA and a pair of HsPEX6-specific PCR primers: a sense forward (F)1: 5Ј-GTCCTG TCACCATGGCGC-3Ј (initiation codon, underlined) and an antisense reverse (R)1: 5Ј-(CTGGGTCTAGA)CTA GCAGGCAGCAAACTTGCGCTGGATGCGC-3Ј (XbaI site, in parenthesis; termination codon, underlined), containing nucleotide residues at positions Ϫ11 to 7 (A starting in the initiation codon as 1) and 2913-2943, to cover a full length of the PEX6 open reading frame. Amplification was done using the RT product as a template, with a forward primer F1 and a reverse XN.R: 5Ј-GCTAGCTG(ATGCAT)GTTCACCTCCTGGCCCAG-3Ј (NsiI site, in parenthesis; residues at 1840-1871). Amplification was, likewise, performed by the use of a set of primers: a forward F4, 5Ј-AGATGGACCAGCCAGTGC-3Ј (residues at 1179-1196), and a reverse R1, as well as another set: a forward F2-1, 5Ј-GGTTGGGCACTG CTTGGCAC-3Ј (residues at 310-329), and R2, 5Ј-GCCAAAGAGTCCAGTTCATC-3Ј (residues at 2407-2426). Respective cDNA clones were cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and were sequenced.
Genomic DNA was prepared from cultured fibroblasts, as described (Laird et al. 1991) . To determine the zygosity of the mutant PEX6 alleles (see Fig. 2 ) in patient PBD6-01, PCR was performed to amplify the sequence encompassing nucleotide residues 619-882 in the human PEX6 gene (GenBank accession number, AF108095-AF108098) (Zhang et al. 1999) , using a pair of PEX6-specific primers, a forward F3-1: 5Ј-CTTTTAATCTTGGCTGTGAC-3Ј (nucleotide residues at 833-852 in exon 1) and a reverse 42.R: 5Ј-CCGTCATAATTTCCATTAGTG-3Ј (residues at 996-1016 in exon 2), and another set of primers, a forward F2: 5Ј-GGGCTCGGACCGCGAGTC-3Ј (residues at 343-360 in exon 1) and a reverse IVS1-R: 5Ј-CGGCTAGAA ACATTATGTTCA-3Ј (residues at 109-129 in intron 1). Next, to amplify the sequence between nucleotide residues at 2095-2362, PCR was, likewise, done using a set of primers, a forward F6: 5Ј-TGGCAGGTGGCTTGACTG-3Ј (nucleotide residues at 1964-1981 in exon 10) and a reverse R2 (see above). PCR products were cloned into pGEM-T Easy vector and sequenced.
Generation of mutant constructs
An expression vector carrying the patient PBD6-01-derived PEX6 was constructed as follows. PCMVSPORT·HsPEX6 was first digested with XbaI and HindIII, blunted, and then ligated. A 264-bp deleted form of PEX6, termed PEX6del619-882 (see Results), in pCMVSPORT was formed by replacing a BssHII-XhoI fragment of the pCMVSPORT·HsPEX6 with a BssHII-XhoI fragment of the patient PBD6-01-derived PEX6del619-882 in pGEM-T Easy vector. The other mutant type, termed PEX6del2095-2362/21ins, with a 268-bp deletion at positions from 2095 to 2362, plus a following 21-bp insertion, was constructed by replacing a XhoI-NotI fragment of the pCMVSPORT·HsPEX6 with a XhoI-NotI fragment of the patient-derived PEX6del2095-2362/21ins in pGEM-T Easy vector. Both constructs were confirmed by nucleotide sequence analysis.
Results and discussion
CG analysis
In the present work, as a step toward searching for a complementing cDNA for CG6, we first re-evaluated CG analysis of PBD6-01 fibroblasts, basically by cell fusion and PEX gene transfection. In the patient's fibroblasts, peroxisomes were not detected when the cells were immunostained with an anti-catalase antibody (Fig. 1a) . Peroxisome-positive cells were occasionally discernible by cell staining, using antibody to peroxisomal targeting signal type 1 (called PTS1) (data not shown). We performed cell fusion between CG6 PBD6-01 fibroblasts and fibroblasts from a PEX6-defective CG4 patient (PBDC-03) with ZS (Fukuda et al. 1996) , as well as a PEX1-defective CG1 ZS patient (PBDE-14) . Numerous peroxisomes were detected 3 days after the fusion of PBD6-01 fibroblasts with CG1 cells, as assessed by staining with anticatalase antibody (Fig. 1d) , whereas no peroxisome was visible in cells fused with CG4 fibroblasts (Fig. 1b) . Moreover, cell fusion of PBD6-01 fibroblasts with a CHO pex6 mutant ZP92 did not restore peroxisomal protein import, while a cell hybrid with a pex1 ZP107 showed numerous catalase-positive structures, i.e., peroxisomes (Fig. 1, c and   e ). These observations suggested that CG6 is the same CG as PEX6-defective CG4. The formation of peroxisomes was, likewise, observed after cell fusion between PBD6-01 fibroblasts and fibroblasts from the other 10CGs of PBDs (data not shown). We have observed that PBD6-01 fibroblasts are unstable with respect to peroxisome deficiency, perhaps representing a mosaicism of peroxisomes in this NALD patient, and having led us to the previous conclusion, i.e., assignment of PBD6-01 to CG6. It is of interest to note that the very early development of the patient PBD6-01 was not considered abnormal (Kelly et al. 1986 ), suggesting that, in vivo, the peroxisomal protein import deficit was not complete.
We cloned human PEX6 cDNA, encoding a 980-aminoacid AAA ATPase family peroxin, by colony hybridization of a human liver cDNA library . Sequencing of one full-length cDNA out of several clones showed a single base-change in a codon for Pro 939 (CCA) (Fukuda et al. 1996; Yahraus et al. 1996) to Gln 939 (CAA), implying a single nucleotide polymorphism in PEX6 (GenBank accession number, AB051076). We then introduced this PEX6 cDNA into PBD CG6 fibroblasts by electroporation. Numerous peroxisomes were detected 3 days post-transfection ( Fig. 2A, a) . Expression of Pex6p possessing Pro 939 , likewise, complemented peroxisome biogenesis (data not shown). PBD6 fibroblasts were also transfected with human PEX1 cDNA encoding another AAA-family peroxin with a mass of 143 kDa. Peroxisomes were not evident in the transfectants (data not shown). Furthermore, no complementation was evident upon transfection of PBD6 fibroblasts with other human PEX cDNAs (data not shown). Therefore, PEX6 was most likely to be impaired in CG6 PBDs.
Mutation analysis
To determine the dysfunction of PEX6 in PBD6-01 fibroblasts, we performed reverse transcription (RT)-PCR, using poly(A) ϩ RNA and a pair of HsPEX6-specific PCR primers: a sense F1 and an antisense R1. Amplification was done using the RT product as a template with a forward primer F1 and a reverse XN.R. Amplification was, likewise, performed by the use of a set of primers: a forward F4 and a reverse R1, as well as another set: a forward F2-1 and R2. Subsequent sequencing of the respective cDNA clones revealed that 7 of 12 clones had a 264-bp deletion of nucleotide residues at positions from 619 to 882, termed PEX6del619-882, resulting in an 88-amino-acid truncation in one allele (Fig. 2B, upper panel) (GenBank accession number, AB051077). Of note, these clones showed Pro 939 (see above). The truncated sequence corresponded to about one-third of the 3Ј-side of exon 1 (Zhang et al. 1999 ). Another type of mutation was identified in 6 of 10 clones: a 268-bp deletion at positions from 2095 to 2362, plus a following 21-bp insertion, termed PEX6del2095-2362/21ins, resulting in the amino-acid sequence from the N-terminus to the residue at 698 of the normal Pex6p, followed by a distinct 40-amino-acid sequence and a termination (Fig. 2B,   Fig. 1 . Cell fusion analysis. Fibroblasts from a complementation group (CG)6 neonatal adrenoleukodystrophy (NALD) patient (PBD6-01) were fused with peroxisome-deficient cells of other CGs. a, CG6 PBD6-01 fibroblasts; b and c, cell fusion was done with fibroblasts from a PEX6-defective CG4 Zellweger syndrome (ZS) patient and Chinese hamster ovary (CHO) pex6 mutant cells, respectively; d and e, PBD6-01 fibroblasts fused with PEX1-deficient CG1 patient's fibroblasts and CHO pex1 mutant ZP107, respectively. Cells were stained with antihuman catalase antibody. Note that peroxisomes were restored in d and e, but not in b and c. Bar 30 µm lower panel) (GenBank accession number, AB051078). These mutated forms of PEX6 possessed Gln 939 (see above). The deleted sequence 2095 to 2362 encompasses exons 11 and 12 (Zhang et al. 1999) . These mutations inactivated the function of PEX6, as verified by the expres-sion of PEX6del619-882 and PEX6del2095-2362/ 21ins in PBD6-01 fibroblasts ( Fig. 2A, b and c) , as well as in CHO pex6 ZP92 cells (data not shown), where peroxisomes were not re-established. The data collectively indicate that mutation of PEX6 is the genetic-related cause of CG6 PBDs.
To confirm the mutation sites and zygosity of the mutant alleles, genomic PCR was done to amplify the sequence encompassing nucleotide residues 619-882 in the human PEX6 gene (Zhang et al. 1999) . In 8 of 11 independent clones isolated from PCR products in the search for a deletion of residues at 619-882, we identified a single nucleotide substitution at 399, T AE G (a silent mutation in a codon for , and a 14-bp deletion at 800-813 in exon 1, comprising residues 1-882, which, presumably, gave rise to the deletion of residues 619-882 (data not shown). Three of the 11 clones showed the normal PEX6 sequence. Next, to amplify the sequence between nucleotide residues at 2095-2362, PCR was, likewise, done. In 5 of 6 independent clones, a point mutation, G AE A, at the 3Ј-terminus of exon 12 was identified, which apparently caused a deletion of exons 11 and 12. One of the 6 clones contained the normal PEX6 gene sequence. We interpreted these results to mean that this NALD patient, PBD6-01, was a compound heterozygote for the mutations. Each of the two alleles, the PEX6del619-882 allele, apparently encoding for the Pro 939 -Pex6p truncated at 207-294, and the other ellele, PEX6del2095-2362/21ins, apparently encoding for the Gln 939 -Pex6p with a deletion in the C-terminal part encoded by exons 11 and 12 plus a frameshift/termination, was, most likely, derived from each parent. Accordingly, by merging CG6 with CG4, human PBDs are now classified into 11 CGs of peroxisome-deficient PBDs such as ZS, NALD, and IRD, and one CG of PEX7-defective RCDP, impaired solely in the PTS2 import (Table 1) . Numbers in parentheses represent the previously assigned, distinct CGs PBD, Peroxisomal biogenesis disorders; CHO, Chinese hamster ovary; CG, complementation groups; ZS, Zellweger syndrome; NALD, neonatal adrenoleukodystrophy; IRD, infantile Refsum disease; RCDP, rhizomelic chondrodysplasia punctata a From (Fujiki 2000; Ghaedi et al. 2000) b From Shimozawa et al. 1998) c From (Gould and Valle 2000) 
